SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) was upgraded by research analysts at Citizens Jmp from a “market ...
Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, ...
NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...
Pharmaceutical Technology on MSN3d
Vivace closes $35m in Series D for cancer drug developmentVivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...
Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
Zacks Investment Research on MSN1d
Labcorp is Set to Acquire Select Assets of BioReference Health of OPKLabcorp LH recently entered into an agreement with OPKO Health, Inc. OPK, a multinational biopharmaceutical and diagnostics company, to acquire select assets of the latter’s wholly owned subsidiary, ...
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Agenus in a report issued ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback